IXHL

Dollar change -0.0105
Percentage change -2.38	%

Peers: MNMD CYBN ATAI COMP RLMD CMPS FEMY GHRS AZN

Index	-	P/E	-	EPS (ttm)	-1.25	Insider Own	21.94%	Shs Outstand	93.70M	Perf Week	-2.97%
Market Cap	40.43M	Forward P/E	-	EPS next Y	-1.56	Insider Trans	0.00%	Shs Float	73.14M	Perf Month	95.87%
Enterprise Value	34.01M	PEG	-	EPS next Q	-0.29	Inst Own	0.76%	Short Float	5.40%	Perf Quarter	280.18%
Income	-21.74M	P/S	404.32	EPS this Y	16.52%	Inst Trans	4.13%	Short Ratio	0.03	Perf Half Y	-79.45%
Sales	0.10M	P/B	1.04	EPS next Y	-62.50%	ROA	-130.01%	Short Interest	3.95M	Perf YTD	-79.65%
Book/sh	0.42	P/C	4.99	EPS next 5Y	-	ROE	-201.88%	52W High	3.12 -86.17%	Perf Year	-78.64%
Cash/sh	0.09	P/FCF	-	EPS past 3/5Y	-220.46% -130.90%	ROIC	-289.64%	52W Low	0.08 439.37%	Perf 3Y	-96.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-79.74% -	Gross Margin	100.00%	Volatility	23.03% 30.72%	Perf 5Y	-
Dividend TTM	-	EV/Sales	340.12	EPS Y/Y TTM	-3384.12%	Oper. Margin	-26535.71%	ATR (14)	0.18	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.12	Sales Y/Y TTM	-	Profit Margin	-22186.73%	RSI (14)	46.25	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	2.12	EPS Q/Q	46.80%	SMA20	-37.01%	Beta	2.70	Target Price	-
Payout	-	Debt/Eq	0.23	Sales Q/Q	-	SMA50	7.99%	Rel Volume	0.54	Prev Close	0.44
Employees	9	LT Debt/Eq	0.01	Earnings	May 15 BMO	SMA200	-61.56%	Avg Volume	138.88M	Price	0.43
IPO	Mar 02, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	56.52% 0.00%	Trades		Volume	70,245,365	Change	-2.38%

Aug-08-25 08:00AM	Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea (GlobeNewswire)
Jul-31-25 08:00AM	Incannex Confirms Strong Cash Position; No Plans or Requirement to Fully Utilise ATM in Near Term (GlobeNewswire) -33.52%
Jul-30-25 08:00AM	Incannex Reports Positive Topline Results from RePOSA Phase 2 Trial of IHL-42X (GlobeNewswire) -17.76%
Jul-25-25 07:30AM	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Charlene E. Gamaldo (GlobeNewswire) -35.58%
Jun-24-25 07:30AM	Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch (GlobeNewswire) +10.00%
07:30AM	Loading…
Jun-18-25 07:30AM	Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X (GlobeNewswire)
Jun-17-25 07:30AM	Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy (GlobeNewswire) +5.53%
Jun-12-25 07:30AM	Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution (GlobeNewswire) +14.57%
Jun-03-25 07:30AM	Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program (GlobeNewswire)
May-29-25 07:30AM	Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance (GlobeNewswire)
May-28-25 04:21PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 (Newsfile) -14.78%
07:00AM	Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results (GlobeNewswire)
May-20-25 07:30AM	Incannex Healthcare Inc. Executes Strategic Cancellation of 50.4% of Series A Warrants, Significantly Reducing Potential Dilution (GlobeNewswire) +20.06%
May-16-25 09:00AM	Incannex Announces Potential Reduction of Up to 50.4% of its Series A Warrants (GlobeNewswire)
May-15-25 08:00AM	Incannex Healthcare Inc. Reports Fiscal Third Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -61.64%
08:00AM	Loading…
May-14-25 08:00AM	Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) (GlobeNewswire) +720.63%
Apr-03-25 07:30AM	Incannex Healthcare Completes Phase 2 Enrollment in RePOSA Phase 2/3 Trial of IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA) (GlobeNewswire)
Mar-07-25 02:10PM	Incannex Healthcare Inc. Announces Pricing of $12.5 Million Private Placement Priced at the Market Under Nasdaq Rules (GlobeNewswire) -19.44%
Feb-18-25 05:52PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 2Q 2025 (Newsfile) -8.47%
Feb-14-25 07:30AM	Incannex Healthcare Inc. Reports Fiscal Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Feb-04-25 09:15AM	Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board (GlobeNewswire) +10.87%
Jan-23-25 07:30AM	Incannex Healthcare Announces Positive Topline Results from Pharmacokinetics (PK) Study of IHL-42X, an Oral Combination Medicine for the Treatment of Obstructive Sleep Apnea (GlobeNewswire) -11.95%
Dec-02-24 04:48PM	Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 1Q 2025 (Newsfile)
Nov-14-24 04:05PM	Incannex Healthcare Inc. Reports Fiscal First Quarter 2025 Financial Results and Business Updates (GlobeNewswire) -11.70% -14.53%
Oct-24-24 07:30AM	Incannex Announces Appointment of Dr. Lou Barbato as Chief Medical Officer (GlobeNewswire)
Oct-02-24 04:50PM	Stonegate Initiates Coverage on Incannex Healthcare Inc. (IXHL) (Newsfile)
Sep-30-24 04:01PM	Incannex Healthcare Inc. Reports Fiscal Full Year 2024 Financial Results and Business Updates (GlobeNewswire) -15.58%
Sep-10-24 08:00AM	Incannex Healthcare Announces Strategic Financing for up to $60 Million with Arena Investors (GlobeNewswire)
Sep-09-24 08:00AM	Sleep Apnea Pill: Quantum Research Survey Shows Sleep Apnea Patients Seeking CPAP Alternatives (Newsfile)
Aug-05-24 07:30AM	FDA Review of PsiGAD2 IND complete; clinical trial for Psilocybin Assisted Psychotherapy in Patients with Generalised Anxiety Disorder to Proceed (GlobeNewswire) +11.11%
07:30AM	Loading…
Jul-30-24 07:30AM	Dosing completed in 115 participant bioavailability/bioequivalence clinical trial for proprietary sleep apnea drug candidate IHL-42X (GlobeNewswire) -11.37%
Jul-01-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace)
Jun-27-24 07:34AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) -13.64%
May-30-24 07:30AM	Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea (GlobeNewswire)
May-07-24 07:30AM	Incannex Complete Successful Pre-IND Meeting with the FDA for CannQuit-O for treatment of opioid use disorder (GlobeNewswire)
May-01-24 02:33PM	Stonegate Healthcare Partners Releases Report on Potentially Transformative Therapies for Generalized Anxiety Disorder (GAD) (Newsfile) -7.61%
Apr-16-24 08:00AM	Incannex Healthcare Inc. Quarterly Update, Q1 2024 (GlobeNewswire) -8.30%
Mar-24-24 07:55AM	11 Best ASX Stocks To Buy Now (Insider Monkey)
Feb-28-24 07:30AM	Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder (GlobeNewswire) +48.58%
Feb-16-24 07:30AM	Incannex Completes Successful Pre-IND Meeting with the FDA for CannQuit-N; a Novel Solution for Tobacco Smoking Cessation (GlobeNewswire) +5.68%
Feb-01-24 07:30AM	Clarion Clinics Open for Psychedelic-Assisted Treatments (GlobeNewswire) -6.40%
Jan-24-24 04:05PM	Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis (GlobeNewswire)
Jan-18-24 08:22AM	Incannex Completes Dosing and Therapy in Phase 2 PsiGAD Clinical Trial Assessing Psilocybin-assisted Psychotherapy for Generalized Anxiety Disorder; Data Analysis Commences (GlobeNewswire)
Jan-17-24 07:30AM	Incannex Receives IRB Approval for the RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea (GlobeNewswire)
Dec-21-23 04:05PM	Clarion Clinics Receives Ethics Board Endorsement for the First Dedicated Psychedelic-Assisted Therapy Clinic in Australia (GlobeNewswire) +5.08%
Dec-06-23 07:30AM	Incannex Update on IHL-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea (GlobeNewswire) -22.45%
Nov-29-23 01:40PM	Incannex Healthcare Announces Completion of its Redomiciliation to the United States (GlobeNewswire)
Nov-16-23 08:30AM	Federal Court of Australia Approves Incannex's Re-Domiciliation and Lodgement of Court Orders With ASIC (GlobeNewswire) -12.24%
Sep-08-23 07:30AM	Incannex Announces Participation at the H.C. Wainwright 25th Annual Global Investment Conference - September 11-13, 2023 (GlobeNewswire) +5.56%
Aug-24-23 01:15PM	Incannex preparing psilocybin therapy FDA IND application (News Direct)
07:30AM	Incannex to Prepare FDA IND Application for Psilocybin-assisted Psychedelic Psychotherapy Program, Known as Psi-GAD (GlobeNewswire)
Aug-23-23 11:45AM	Incannex full steam ahead towards sleep apnoea trial (News Direct)
Aug-22-23 07:30AM	Review of IND Application for IHL-42X by US FDA has been completed; Clinical Trial for Patients with Obstructive Sleep Apnoea May Proceed (GlobeNewswire)
Aug-08-23 08:00AM	Clarion Clinics Begins Accepting Registrations for Psychedelic Treatment Interest as Part of Pre-Screening in Readiness for Opening (GlobeNewswire)
Jul-28-23 07:30AM	Incannex Healthcare June 2023 Quarterly Activities Report and Appendix 4C Cash Flow Statement (GlobeNewswire)
Jul-27-23 01:20PM	Incannex thrilled with positive pre-IND meeting for arthritis treatment (News Direct)
Jul-26-23 07:30AM	Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-675A for Treatment of Rheumatoid Arthritis (GlobeNewswire)
Jul-21-23 09:09AM	Incannex Submits IND Application to the US FDA for IHL-42X for Obstructive Sleep Apnoea (GlobeNewswire)
Jul-18-23 02:30PM	Incannex appoints CRO ahead of Phase 2/3 sleep apnoea trial (News Direct)
07:40AM	Incannex engages Fortrea to Manage its FDA IND Opening Phase 2/3 Clinical Trial Investigating IHL-42X for Treatment of Obstructive Sleep Apnoea (GlobeNewswire)
Jul-13-23 08:00AM	Incannex Receives HREC Approval for Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis (GlobeNewswire)
Jul-11-23 03:00PM	Incannex CEO talks plans to redomicile to US (News Direct)
Jul-10-23 07:30AM	Incannex Announces Intention to Redomicile to United States, List all Shares on Nasdaq (GlobeNewswire) +6.25%
Jul-06-23 08:42AM	Incannex Receives Ethics Approval for Bioequivalence/Bioavailability Clinical Trial for IHL-42X, the Companys Proprietary Drug for Treatment of Obstructive Sleep Apnoea (OSA) (GlobeNewswire) +13.44%
Jun-23-23 08:00AM	Incannex Announces Participation at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference June 26, 2023 (GlobeNewswire)
Jun-19-23 11:20AM	Incannex appoints principal investigators for pivotal IHL-42X trial (News Direct)
Jun-16-23 08:00AM	Incannex Appoints Principal Investigators for IHL-42X Phase 2/3 Clinical Trial (GlobeNewswire)
Jun-01-23 12:15PM	Incannex welcomes world-leading psychedelics experts to advisory board (News Direct)
May-30-23 08:00AM	World Renowned International Psychedelics Experts Join Clarion Clinics Advisory Board (GlobeNewswire)
May-16-23 07:50AM	Incannex Company Presentation Presentation of Psychennex, Psychedelic Therapies Subsidiary Company (GlobeNewswire)
May-05-23 07:30AM	Incannex enters a lease for first psychedelic-assisted psychotherapy clinic (GlobeNewswire)
May-03-23 02:20PM	Incannex readying for Phase 2 clinical trial of anti-inflammatory drug IHL-675A (News Direct)
07:30AM	Incannex Company Presentation Results from Phase 1 Clinical Trial to Assess Proprietary IHL-675A (GlobeNewswire)
May-02-23 07:30AM	Incannex Announces Final Results from Phase 1 Clinical Trial Assessing Safety and Pharmacokinetics of IHL-675A (GlobeNewswire) -5.10%
Apr-25-23 08:00AM	PharmAla Biotech to supply Incannex with GMP LaNeo MDMA and Psilocybin (GlobeNewswire)
Apr-14-23 07:30AM	Incannex Appoints QPS to Advance CannQuit-N (Nicotine), CannQuit-O (Opioid) and Renecann Products in the USA and EU (GlobeNewswire) -6.64%
Mar-16-23 08:51AM	Incannex to Commercialise its Psychedelic Clinics Business in Collaborative Partnership with Leading Psychedelic Experts (GlobeNewswire) -8.62%
Mar-15-23 12:55PM	Why Incannex Healthcare Shares Are Gaining Today (Benzinga)
07:30AM	Interim review of proprietary PsiGAD clinical trial data indicates no safety concerns and projects a statistically significant benefit for the psilocybin arm versus the placebo arm in those participants who have completed the treatment (GlobeNewswire)
Mar-03-23 01:30PM	Incannex to work with Catalent to produce psilocybin for clinical and potentially commercial use (News Direct)
07:30AM	Incannex Engages Catalent for Development and cGMP Manufacture of Psilocybin Drug Product for Clinical Trials and Potential Commercial Use (GlobeNewswire)
Feb-28-23 05:30PM	Incannex Healthcare kicks off Phase 2 rheumatoid arthritis trial (News Direct) +5.81%
07:25AM	Incannex Commences Phase 2 Clinical Trial Assessing IHL-675A for use in Treatment of Pain and Function in Rheumatoid Arthritis (GlobeNewswire)
Jan-18-23 08:00AM	Independent data review commences for Phase 2 trial of psilocybin-assisted psychotherapy for anxiety (GlobeNewswire) +8.00%
Dec-06-22 08:00AM	Incannex Expands Intellectual Property Position over IHL-42X (GlobeNewswire) -19.11%
Nov-29-22 08:00AM	Incannex Engages Eurofins to Manufacture ReneCann Therapeutic Topical Application for Immune Disordered Skin Diseases (GlobeNewswire)
Nov-28-22 08:00AM	Incannex Engages Eurofins to Manufacture Novel Addiction Treatments CannQuit-N and CannQuit-O (GlobeNewswire)
Nov-17-22 08:00AM	Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (OSA) (GlobeNewswire)
Oct-28-22 08:00AM	Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement (GlobeNewswire)
Oct-13-22 08:00AM	Incannex Completes Dosing in Phase 1 Clinical Trial to Assess Multi-Use, Anti-Inflammatory Drug IHL-675A; Proceeds to Phase 2 Clinical Trials (GlobeNewswire)
Oct-11-22 08:00AM	Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic Brain Injury (GlobeNewswire)
Sep-08-22 09:15AM	Incannex to Participate in the Prestigious H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
Aug-17-22 08:00AM	Incannex Appoints FDA Regulatory Affairs Expert Mr Robert B. Clark to the Board of Directors (GlobeNewswire)
Aug-10-22 04:36PM	Do Institutions Own Incannex Healthcare Limited (ASX:IHL) Shares? (Simply Wall St.)
Aug-02-22 07:55AM	Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A (PR Newswire)
Jul-27-22 07:55AM	Incannex Healthcare Quarterly Activities Report and Appendix 4C Cash Flow Statement (PR Newswire)
Jul-21-22 07:55AM	Incannex Receives Ethics Approval to Commence Phase 1 Clinical Trial of Multi-Use Anti-Inflammatory Drug IHL-675A (PR Newswire) +10.86%
Jun-27-22 06:55AM	Incannex to Present at the H.C. Wainwright First Annual Mental Health Conference (PR Newswire)
Jun-03-22 07:55AM	Incannex announces positive results from phase 2 clinical trial investigating the effect of IHL-42X for treatment of obstructive sleep apnoea (PR Newswire)
May-17-22 07:55AM	Incannex Announces Positive Pre-IND Meeting with U.S. FDA for IHL-42X for Obstructive Sleep Apnoea (PR Newswire) +10.24%

Incannex Healthcare, Inc. is a biotech company, which engages in developing cannabinoid and psychedelic compound medicines. It focuses on the research and development for medicinal cannabis pharmaceutical products and psychedelic medicine therapies for treatment of a range of indications. The company was founded on July 5, 2023 and is headquartered in Norwest, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Incannex Healthcare Inc

Upgrade your FINVIZ experience